Back to today’s briefing

Story perspectives

Shingrix Cuts Cardiovascular Events 12% Versus Zostavax

8/26/2026

27 4 Full Breakdown

Summary

Story summary

U.S. researchers found Shingrix lowered cardiovascular events versus Zostavax.
In a study of 70,000 adults 60+, Shingrix cut heart attacks, strokes and heart failure by 12%.
After 3.5 years, Shingrix was linked to a 4% lower overall cardiovascular disease risk.
Researchers say vaccinating U.S. adults 50+ could prevent hundreds of thousands of cases in a decade.
Researchers used the October 2017 switch from Zostavax to Shingrix as an experiment.

1 of 1

Story summary

U.S. researchers found Shingrix lowered cardiovascular events versus Zostavax.
In a study of 70,000 adults 60+, Shingrix cut heart attacks, strokes and heart failure by 12%.
After 3.5 years, Shingrix was linked to a 4% lower overall cardiovascular disease risk.
Researchers say vaccinating U.S. adults 50+ could prevent hundreds of thousands of cases in a decade.
Researchers used the October 2017 switch from Zostavax to Shingrix as an experiment.